Difference between revisions of "HAEM5:Volunteer Assignments and Opportunities"
[unchecked revision] | [unchecked revision] |
(Updated) |
|||
(36 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
Welcome! | Welcome! | ||
− | *For assignments, please see the "Author" column below ( | + | '''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.''' |
+ | |||
+ | *For assignments, please see the "Author" column below (highlighted blue). | ||
+ | |||
+ | *If empty (no name is present), please volunteer to create content for that disease! | ||
+ | *If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content. | ||
+ | |||
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | *To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | ||
− | *Note - NEW (No Prior) means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content added. | + | *Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added. |
<br /> | <br /> | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
− | |+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues ( | + | |+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big> |
|- | |- | ||
− | !Disease (5th Edition)!!Page Type!!Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition) | + | !Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition) |
+ | !Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition) | ||
!Correlated Prior Disease Name (4th Edition) | !Correlated Prior Disease Name (4th Edition) | ||
!Correlated Prior Author (4th Edition) | !Correlated Prior Author (4th Edition) | ||
Line 46: | Line 53: | ||
----<br /> | ----<br /> | ||
|- | |- | ||
− | |[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || | + | |[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra |
+ | |4/8/24 | ||
+ | | ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 60: | Line 69: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| || |
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | ||
|Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
Line 67: | Line 76: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| | + | |[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Chronic Neutrophilic Leukemia (CNL) | |Chronic Neutrophilic Leukemia (CNL) | ||
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | ||
Line 74: | Line 84: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| | + | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified | |Chronic Eosinophilic Leukemia, Not Otherwise Specified | ||
|Chelsea D. Kramish; Daynna J.Wolff | |Chelsea D. Kramish; Daynna J.Wolff | ||
Line 81: | Line 92: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| | + | |[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Polycythemia Vera (PV) | |Polycythemia Vera (PV) | ||
|Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | ||
Line 88: | Line 100: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| | + | |[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Essential Thrombocythemia (ET) | |Essential Thrombocythemia (ET) | ||
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | ||
Line 95: | Line 108: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| | + | |[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Primary Myelofibrosis (PMF) | |Primary Myelofibrosis (PMF) | ||
|T. Niroshi Senaratne, UCLA | |T. Niroshi Senaratne, UCLA | ||
Line 102: | Line 116: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | | + | |[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING |
+ | | || || || ||FQR|| || | ||
|Juvenile Myelomonocytic Leukemia (JMML) | |Juvenile Myelomonocytic Leukemia (JMML) | ||
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> | |<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> | ||
Line 113: | Line 128: | ||
|FQR has emailed SR several times, last 4/20/22 | |FQR has emailed SR several times, last 4/20/22 | ||
|- | |- | ||
− | |[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| | + | |[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Myeloproliferative Neoplasm (MPN), Unclassifiable | |Myeloproliferative Neoplasm (MPN), Unclassifiable | ||
|Thomas Lee, MD, PhD, University of California, Los Angeles | |Thomas Lee, MD, PhD, University of California, Los Angeles | ||
Line 120: | Line 136: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| | + | |[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Cutaneous Mastocytosis | |Cutaneous Mastocytosis | ||
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | |S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | ||
Line 127: | Line 144: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| || | + | |[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| || |
|Systemic Mastocytosis | |Systemic Mastocytosis | ||
− | | | + | |Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University |
|Complete | |Complete | ||
| | | | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| | + | |[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Mast Cell Sarcoma | |Mast Cell Sarcoma | ||
|Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | |Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | ||
Line 141: | Line 159: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| | + | |[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q) | |Myelodysplastic Syndrome (MDS) with Isolated del(5q) | ||
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | |Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | ||
Line 148: | Line 167: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| | + | |[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 176: | Line 196: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| | + | |[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Myelodysplastic Syndrome (MDS) with Excess Blasts | |Myelodysplastic Syndrome (MDS) with Excess Blasts | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
Line 183: | Line 204: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| | + | |[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Refractory Cytopenia of Childhood | |Refractory Cytopenia of Childhood | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
Line 190: | Line 212: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| | + | |[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Refractory Cytopenia of Childhood | |Refractory Cytopenia of Childhood | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
Line 197: | Line 220: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| | + | |[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Chronic Myelomonocytic Leukemia (CMML) | |Chronic Myelomonocytic Leukemia (CMML) | ||
|Linsheng Zhang, MD, PhD | |Linsheng Zhang, MD, PhD | ||
Line 204: | Line 228: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| | + | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | |Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | ||
|Linsheng Zhang, MD, PhD | |Linsheng Zhang, MD, PhD | ||
Line 211: | Line 236: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| | + | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | |Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | ||
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | |Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | ||
Line 218: | Line 244: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| | + | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING |
+ | | || || || ||FQR|| || | ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | |Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | ||
|Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | |Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | ||
Line 227: | Line 254: | ||
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | |[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 243: | Line 270: | ||
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 259: | Line 286: | ||
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | |[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 275: | Line 302: | ||
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | |[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 291: | Line 318: | ||
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | |[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 307: | Line 334: | ||
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 323: | Line 350: | ||
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 339: | Line 366: | ||
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 371: | Line 398: | ||
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | |[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 387: | Line 414: | ||
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | |[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 403: | Line 430: | ||
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | |[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 435: | Line 462: | ||
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | |[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 451: | Line 478: | ||
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | |[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 467: | Line 494: | ||
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | |[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 483: | Line 510: | ||
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | |[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 499: | Line 526: | ||
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | |[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 515: | Line 542: | ||
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | |[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 531: | Line 558: | ||
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | |[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 547: | Line 574: | ||
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | |[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 563: | Line 590: | ||
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | |[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 598: | Line 625: | ||
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | |[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 614: | Line 641: | ||
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | |[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 630: | Line 657: | ||
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | |[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 646: | Line 673: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 662: | Line 689: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 678: | Line 705: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 761: | Line 788: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] | |[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
+ | |Tracy Tucker, PhD, FCCMG | ||
+ | |4/6/24 | ||
| | | | ||
− | | | + | |Pending |
− | |||
− | |||
| | | | ||
|JH_MS | |JH_MS | ||
Line 777: | Line 804: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | |[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
+ | |Tracy Tucker, PhD, FCCMG | ||
+ | |4/6/24 | ||
| | | | ||
− | | | + | |Pending |
− | |||
− | |||
| | | | ||
|JH_MS | |JH_MS | ||
Line 809: | Line 836: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | |[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 825: | Line 852: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] | |[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 841: | Line 868: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | |[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 873: | Line 900: | ||
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | |[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 935: | Line 962: | ||
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | |[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 951: | Line 978: | ||
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | |[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 967: | Line 994: | ||
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | |[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,079: | Line 1,106: | ||
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | |[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,189: | Line 1,216: | ||
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | |[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,205: | Line 1,232: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,221: | Line 1,248: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,237: | Line 1,264: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,253: | Line 1,280: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | ||
|Disease | |Disease | ||
− | |Holli | + | |Holli Drendel |
− | |||
| | | | ||
| | | | ||
+ | |?Complete? Looks like tables need more editing. | ||
| | | | ||
|HD | |HD | ||
Line 1,269: | Line 1,296: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,285: | Line 1,312: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,301: | Line 1,328: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,317: | Line 1,344: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,349: | Line 1,376: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,365: | Line 1,392: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,446: | Line 1,473: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease|| | + | |[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty |
+ | | || || || ||Shivani Golem (SG) | ||
| || | | || | ||
|Monoclonal B-cell Lymphocytosis | |Monoclonal B-cell Lymphocytosis | ||
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | |Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | ||
− | |PENDING | + | |PENDING, 4/30/2024 |
| | | | ||
|Assigned 12/19/2022 with completion date of 1/19/2023 | |Assigned 12/19/2022 with completion date of 1/19/2023 | ||
Line 1,459: | Line 1,487: | ||
Honey Reddi, PhD, Belay Diagnostics | Honey Reddi, PhD, Belay Diagnostics | ||
− | | || ||Complete | + | | || ||Complete|| ||SG|| || |
|Already converted to 5th edition | |Already converted to 5th edition | ||
|Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | |Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | ||
Line 1,466: | Line 1,494: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| | + | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| |
+ | | || || || ||SG|| || | ||
|Hairy Cell Leukemia | |Hairy Cell Leukemia | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
Line 1,473: | Line 1,502: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| | + | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| |
+ | | || || || ||SG|| || | ||
|Splenic Marginal Zone Lymphoma | |Splenic Marginal Zone Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
Line 1,480: | Line 1,510: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | + | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| |
+ | | || || || ||SG|| || | ||
|Splenic Diffuse Red Pulp Small B-cell Lymphoma | |Splenic Diffuse Red Pulp Small B-cell Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
Line 1,505: | Line 1,536: | ||
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | |[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,521: | Line 1,552: | ||
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | |[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,555: | Line 1,586: | ||
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | |[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,571: | Line 1,602: | ||
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | |[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,619: | Line 1,650: | ||
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | |[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,651: | Line 1,682: | ||
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | |[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,667: | Line 1,698: | ||
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | |[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,683: | Line 1,714: | ||
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] | |[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] | ||
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 1,692: | Line 1,723: | ||
| | | | ||
|Mantle Cell Lymphoma | |Mantle Cell Lymphoma | ||
− | | | + | |Mahsa Khanlari, MD and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas |
|Pending | |Pending | ||
| | | | ||
Line 1,729: | Line 1,760: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | + | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified | ||
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | |Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | ||
Line 1,743: | Line 1,775: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| | + | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | |High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
Line 1,750: | Line 1,783: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | + | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|ALK-Positive Large B-cell Lymphoma | |ALK-Positive Large B-cell Lymphoma | ||
|Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | ||
Line 1,757: | Line 1,791: | ||
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | ||
|- | |- | ||
− | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | + | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Large B-cell Lymphoma with IRF4 Rearrangement | |Large B-cell Lymphoma with IRF4 Rearrangement | ||
|Afia Hasnain, MBBS, PhD | |Afia Hasnain, MBBS, PhD | ||
Line 1,764: | Line 1,799: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | + | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Burkitt-Like Lymphoma with 11q Aberration | |Burkitt-Like Lymphoma with 11q Aberration | ||
|Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | ||
Line 1,778: | Line 1,814: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || | | + | |[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor |
+ | |3/22/24|| ||Pending|| ||GC|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,792: | Line 1,829: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | + | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||PENDING |
+ | | || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | ||
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | |Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,806: | Line 1,844: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | + | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Plasmablastic Lymphoma | |Plasmablastic Lymphoma | ||
|Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
Line 1,813: | Line 1,852: | ||
| | | | ||
|- | |- | ||
− | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| | + | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | |(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | ||
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | |(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
Line 1,827: | Line 1,867: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| | + | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Intravascular Large B-cell Lymphoma | |Intravascular Large B-cell Lymphoma | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | ||
Line 1,848: | Line 1,889: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | + | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | |High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Aiko Otsubo, PhD, Indiana University, Holli Drendel | |Aiko Otsubo, PhD, Indiana University, Holli Drendel | ||
Line 1,855: | Line 1,897: | ||
| | | | ||
|- | |- | ||
− | |Burkitt lymphoma||Disease|| | + | |[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||PENDING |
+ | | || || || ||GC|| || | ||
|Burkitt Lymphoma | |Burkitt Lymphoma | ||
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland | |Becky Leung, MBBS (Hons), BSc, Pathology Queensland | ||
Line 1,862: | Line 1,905: | ||
| | | | ||
|- | |- | ||
− | |Primary effusion lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,869: | Line 1,912: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,876: | Line 1,919: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| || | + | |[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,883: | Line 1,926: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Hyperplasias arising in immune deficiency/dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others")|| || || || ||GC|| || | + | |[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content. What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| || |
| | | | ||
| | | | ||
Line 1,890: | Line 1,933: | ||
| | | | ||
|- | |- | ||
− | |Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]]. | + | |[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]]. |
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)" | Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)" | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
Line 1,899: | Line 1,942: | ||
| | | | ||
|- | |- | ||
− | |EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| || | + | |[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,906: | Line 1,949: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Lymphomas arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| || | + | |[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| || |
| | | | ||
| | | | ||
Line 1,913: | Line 1,956: | ||
| | | | ||
|- | |- | ||
− | |Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]")|| || || || ||GC|| || | + | |[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| || |
| | | | ||
| | | | ||
Line 1,920: | Line 1,963: | ||
| | | | ||
|- | |- | ||
− | |Classic Hodgkin lymphoma||Disease|| || || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | + | |[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||PENDING |
− | + | | || || || | |
+ | |GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | |(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | |(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | ||
Line 1,928: | Line 1,972: | ||
| | | | ||
|- | |- | ||
− | |Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease|| || || || || ||GC|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,935: | Line 1,979: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Cold agglutinin disease | + | |[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]] |
|Disease | |Disease | ||
| | | | ||
Line 1,951: | Line 1,995: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | + | |[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,958: | Line 2,002: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | + | |[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,965: | Line 2,009: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG | + | |[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG |
| || | | || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,973: | Line 2,017: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Immunoglobulin-related (AL) amyloidosis||Disease|| | + | |[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||PENDING |
+ | | || || || ||SG | ||
| || | | || | ||
|Primary Amyloidosis | |Primary Amyloidosis | ||
Line 1,981: | Line 2,026: | ||
| | | | ||
|- | |- | ||
− | |Monoclonal immunoglobulin deposition disease||Disease|| | + | |[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||PENDING |
+ | | || || || ||SG | ||
| || | | || | ||
|Light Chain and Heavy Chain Deposition Disease | |Light Chain and Heavy Chain Deposition Disease | ||
Line 1,989: | Line 2,035: | ||
| | | | ||
|- | |- | ||
− | |Mu heavy chain disease||Disease|| || || || || ||SG | + | |[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG |
| || | | || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 1,997: | Line 2,043: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Gamma heavy chain disease||Disease|| | + | |[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||PENDING |
+ | | || || || ||SG | ||
| || | | || | ||
|Gamma Heavy Chain Disease | |Gamma Heavy Chain Disease | ||
Line 2,005: | Line 2,052: | ||
| | | | ||
|- | |- | ||
− | |Alpha heavy chain disease||Disease|| || || || || ||SG | + | |[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG |
| || | | || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,013: | Line 2,060: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Plasmacytoma||Disease|| || || || | | + | |[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||PENDING |
+ | | || || || | ||
|SG | |SG | ||
− | | || | + | | ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) |
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | |NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,022: | Line 2,070: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Plasma cell myeloma / multiple myeloma||Disease|| || || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | + | |[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||PENDING |
− | + | | || || || ||SG | |
+ | | ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | ||
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | ||
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | |(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | ||
Line 2,030: | Line 2,079: | ||
| | | | ||
|- | |- | ||
− | |Plasma cell neoplasms with associated paraneoplastic syndrome||Disease|| || || || | | + | |[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING |
+ | | || || || | ||
|SG | |SG | ||
− | | || | + | | ||Note: author needs to include POEMS, TEMPI, and look for AESOP content |
|(1) POEMS Syndrome + (2) TEMPI Syndrome | |(1) POEMS Syndrome + (2) TEMPI Syndrome | ||
|(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | |(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | ||
Line 2,038: | Line 2,088: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |Disease (5th Edition) | ||
+ | |Page Type | ||
+ | |Author (5th Edition) (Note: please indicate trainees in parenthesis) | ||
+ | |Date Assigned to Author (5th Edition) | ||
+ | |Target Completion Date (5th Edition) | ||
+ | |Content Status (5th Edition) (Pending or Complete) | ||
+ | |Date Completed by Author (5th Edition) | ||
+ | |Associate Editor | ||
+ | |Date of Last Editor Review (5th Edition) | ||
+ | |Notes (5th Edition) | ||
+ | |Correlated Prior Disease Name (4th Edition) | ||
+ | |Correlated Prior Author (4th Edition) | ||
+ | |Prior Content Status (4th Edition) (Pending or Complete) | ||
+ | |Prior Date of Last Editor Review (4th Edition) | ||
+ | |Prior Notes (4th Edition) | ||
|- | |- | ||
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | |CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | ||
Line 2,069: | Line 2,135: | ||
----<br /> | ----<br /> | ||
|- | |- | ||
− | |Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK) | + | |[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK) |
| || | | || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,077: | Line 2,143: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Autoimmune lymphoproliferative syndrome||Disease|| | | + | |[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD |
+ | |3/25/2024 | ||
+ | | || || ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,084: | Line 2,152: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,091: | Line 2,159: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || || | + | |[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,098: | Line 2,166: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Early T-precursor lymphoblastic leukaemia / lymphoma | + | |[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]] |
|Disease | |Disease | ||
+ | |Fei Yang, MD | ||
| | | | ||
| | | | ||
+ | |Pending | ||
| | | | ||
− | | | + | |SK |
− | |||
− | |||
| | | | ||
| | | | ||
Line 2,114: | Line 2,182: | ||
| | | | ||
|- | |- | ||
− | |T-prolymphocytic leukaemia | + | |[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] |
|Disease | |Disease | ||
+ | |Parastou Tizro, MD (trainee); | ||
+ | Sumire Kitahara, MD | ||
+ | |3/17/2024 | ||
| | | | ||
− | | | + | |Pending |
− | |||
− | |||
| | | | ||
|SK | |SK | ||
Line 2,130: | Line 2,199: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |T-large granular lymphocytic leukaemia||Disease|| || | | + | |[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS |
+ | |3/17/2024 | ||
+ | |6/30/24 | ||
+ | |Pending | ||
+ | | ||SK|| || | ||
|T-cell Large Granular Lymphocytic Leukemia | |T-cell Large Granular Lymphocytic Leukemia | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
Line 2,137: | Line 2,210: | ||
| | | | ||
|- | |- | ||
− | |NK-large granular lymphocytic leukaemia||Disease|| || | | + | |[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee); |
+ | Michelle Don, MD, MS | ||
+ | |3/17/2024 | ||
+ | |6/30/24 | ||
+ | |Pending | ||
+ | | ||SK|| || | ||
|Chronic Lymphoproliferative Disorder of NK Cells | |Chronic Lymphoproliferative Disorder of NK Cells | ||
|Michelle Don, MD | |Michelle Don, MD | ||
Line 2,144: | Line 2,222: | ||
| | | | ||
|- | |- | ||
− | |Adult T-cell leukaemia/lymphoma||Disease|| | + | |[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease|| |
+ | | || || || ||SK|| || | ||
|Adult T-cell Leukemia/Lymphoma | |Adult T-cell Leukemia/Lymphoma | ||
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | |Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | ||
Line 2,151: | Line 2,230: | ||
| | | | ||
|- | |- | ||
− | |Sezary syndrome||Disease|| | | + | |[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD |
+ | |3/22/2024 | ||
+ | | || || ||SK|| || | ||
|Sézary Syndrome | |Sézary Syndrome | ||
|Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | |Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | ||
Line 2,158: | Line 2,239: | ||
| | | | ||
|- | |- | ||
− | |Aggressive NK-cell leukaemia||Disease|| | + | |[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Aggressive NK-cell Leukemia | |Aggressive NK-cell Leukemia | ||
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD | |Shanelle De Lancy, MD, Shashirekha Shetty, PhD | ||
Line 2,165: | Line 2,247: | ||
| | | | ||
|- | |- | ||
− | |Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || | + | |[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc |
+ | |3/19/2024 | ||
+ | | ||Pending | ||
+ | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,172: | Line 2,257: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || | + | |[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee), |
+ | |||
+ | Andrew Siref, MD | ||
+ | |4/12/2024 | ||
+ | | ||Pending | ||
+ | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,179: | Line 2,269: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Mycosis fungoides||Disease|| | | + | |[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD |
+ | |3/22/2024 | ||
+ | | || || ||SK|| || | ||
|Mycosis Fungoides | |Mycosis Fungoides | ||
|Jane Scribner, MD and Daynna J. Wolff, PhD | |Jane Scribner, MD and Daynna J. Wolff, PhD | ||
Line 2,186: | Line 2,278: | ||
| | | | ||
|- | |- | ||
− | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease|| || || || || ||SK|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,193: | Line 2,285: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease|| | + | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||PENDING |
+ | | || || || ||SK|| || | ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma | |Primary Cutaneous Anaplastic Large Cell Lymphoma | ||
|Theresa Spivey, MD, Shashirekha Shetty, PhD | |Theresa Spivey, MD, Shashirekha Shetty, PhD | ||
Line 2,200: | Line 2,293: | ||
| | | | ||
|- | |- | ||
− | |Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || | + | |[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee) |
+ | |3/19/2024 | ||
+ | | ||Pending | ||
+ | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,207: | Line 2,303: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Primary cutaneous gamma/delta T-cell lymphoma||Disease|| | + | |[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD |
+ | | || || || ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,214: | Line 2,311: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || | | + | |[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee), |
+ | |||
+ | Andrew Siref, MD | ||
+ | |4/12/2024|| ||Pending | ||
+ | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,221: | Line 2,322: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,228: | Line 2,329: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Indolent T-cell lymphoma of the gastrointestinal tract||Disease|| | + | |[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| |
+ | | || || || ||SK|| || | ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | |Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | ||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | ||
Line 2,235: | Line 2,337: | ||
| | | | ||
|- | |- | ||
− | |Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,242: | Line 2,344: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Enteropathy-associated T-cell lymphoma||Disease|| || || | + | |[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), |
+ | Andrew Siref, MD | ||
+ | |3/20/2024 | ||
+ | | ||Pending|| ||SK|| || | ||
|Enteropathy-Associated T-cell Lymphoma | |Enteropathy-Associated T-cell Lymphoma | ||
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | |*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | ||
Line 2,249: | Line 2,354: | ||
| | | | ||
|- | |- | ||
− | |Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease|| || || | + | |[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), |
+ | Andrew Siref, MD | ||
+ | |3/20/2024 | ||
+ | | ||Pending|| ||SK|| || | ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | |Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | ||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | ||
Line 2,256: | Line 2,364: | ||
| | | | ||
|- | |- | ||
− | |Intestinal T-cell lymphoma, NOS||Disease|| | + | |[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease|| |
+ | | || || || ||SK|| || | ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | |Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | |Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | ||
Line 2,263: | Line 2,372: | ||
| | | | ||
|- | |- | ||
− | |Hepatosplenic T-cell lymphoma||Disease|| || | | + | |[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee); |
+ | Michelle Don, MD, MS | ||
+ | |3/19/2024 | ||
+ | |6/30/24 | ||
+ | |Pending | ||
+ | | ||SK|| || | ||
|Hepatosplenic T-cell Lymphoma | |Hepatosplenic T-cell Lymphoma | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
Line 2,270: | Line 2,384: | ||
| | | | ||
|- | |- | ||
− | |ALK-positive anaplastic large cell lymphoma||Disease|| || || | | + | |[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) |
+ | |||
+ | Sumire Kitahara, MD | ||
+ | | || ||Pending | ||
+ | | ||SK|| || | ||
|Anaplastic Large Cell Lymphoma, ALK-Positive | |Anaplastic Large Cell Lymphoma, ALK-Positive | ||
|Miguel Gonzalez Mancera, MD | |Miguel Gonzalez Mancera, MD | ||
Line 2,281: | Line 2,399: | ||
| | | | ||
|- | |- | ||
− | |ALK-negative anaplastic large cell lymphoma||Disease|| || || | | + | |[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee) |
+ | Sumire Kitahara, MD | ||
+ | | || ||Pending | ||
+ | | ||SK|| || | ||
|Anaplastic Large Cell Lymphoma, ALK-Negative | |Anaplastic Large Cell Lymphoma, ALK-Negative | ||
|Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | |Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | ||
Line 2,288: | Line 2,409: | ||
| | | | ||
|- | |- | ||
− | |Breast implant-associated anaplastic large cell lymphoma||Disease|| || || | + | |[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD |
+ | |4/1/2024 | ||
+ | | ||Pending|| ||SK|| || | ||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma | |Breast Implant-Associated Anaplastic Large Cell Lymphoma | ||
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | ||
Line 2,295: | Line 2,418: | ||
| | | | ||
|- | |- | ||
− | |Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease|| | + | |[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 |
− | | ||Pending|| ||SK|| || | + | | ||Pending|| ||SK|| ||prior authors not available |
|Angioimmunoblastic T-cell Lymphoma | |Angioimmunoblastic T-cell Lymphoma | ||
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | |Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | ||
Line 2,303: | Line 2,426: | ||
| | | | ||
|- | |- | ||
− | |Nodal TFH cell lymphoma, follicular-type||Disease||Rachel Burnside||7/28/2023 | + | |[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023 |
| ||Pending|| ||SK|| || | | ||Pending|| ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,311: | Line 2,434: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Nodal TFH cell lymphoma, NOS||Disease|| | + | |[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease|| |
+ | | || || || ||SK|| || | ||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | |Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | ||
|Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | |Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | ||
Line 2,318: | Line 2,442: | ||
| | | | ||
|- | |- | ||
− | |Peripheral T-cell lymphoma, NOS||Disease|| | | + | |[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD |
+ | |6/25/2023 | ||
+ | | || || ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,325: | Line 2,451: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| || | + | |[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,332: | Line 2,458: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Extranodal NK/T-cell lymphoma||Disease|| || || | + | |[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc |
+ | |3/19/2024 | ||
+ | | ||Pending | ||
+ | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,339: | Line 2,468: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Severe mosquito bite allergy||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,346: | Line 2,475: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| || | + | |[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| || |
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,353: | Line 2,482: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Systemic chronic active EBV disease||Disease|| | | + | |[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD |
+ | |3/25/2024 | ||
+ | | || || ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
Line 2,360: | Line 2,491: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
− | |Systemic EBV-positive T-cell lymphoma of childhood||Disease|| | | + | |[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD |
+ | |3/25/2024 | ||
+ | | || || ||SK|| ||prior authors not available | ||
|Systemic EBV-Positive T-cell Lymphoma of Childhood | |Systemic EBV-Positive T-cell Lymphoma of Childhood | ||
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | |Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | ||
Line 2,397: | Line 2,530: | ||
----<br /> | ----<br /> | ||
|- | |- | ||
− | |Follicular dendritic cell sarcoma | + | |[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]] |
|Disease | |Disease | ||
− | | | + | |PENDING |
| | | | ||
| | | | ||
Line 2,407: | Line 2,540: | ||
| | | | ||
| | | | ||
− | | | + | |Follicular Dendritic Cell Sarcoma |
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | |Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | ||
− | | | + | |?Pending |
| | | | ||
| | | | ||
|- | |- | ||
− | |EBV-positive inflammatory follicular dendritic cell sarcoma | + | |[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 2,423: | Line 2,556: | ||
| | | | ||
| | | | ||
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
|- | |- | ||
− | |Fibroblastic reticular cell tumour | + | |[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 2,437: | Line 2,570: | ||
| | | | ||
|GC | |GC | ||
+ | | | ||
+ | | | ||
+ | |NEW (No Prior) | ||
+ | |NEW (No Prior) | ||
+ | |NEW (No Prior) | ||
+ | |NEW (No Prior) | ||
+ | |NEW (No Prior) | ||
+ | |- | ||
+ | |[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 2,442: | Line 2,585: | ||
| | | | ||
| | | | ||
+ | |GC | ||
| | | | ||
| | | | ||
+ | |NEW (No Prior) | ||
+ | |NEW (No Prior) | ||
+ | |NEW (No Prior) | ||
+ | |NEW (No Prior) | ||
+ | |NEW (No Prior) | ||
|- | |- | ||
− | | | + | |[[HAEM5:Littoral cell angioma|Littoral cell angioma]] |
|Disease | |Disease | ||
| | | | ||
Line 2,455: | Line 2,604: | ||
| | | | ||
| | | | ||
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
|- | |- | ||
− | | | + | |[[HAEM5:Splenic hamartoma|Splenic hamartoma]] |
|Disease | |Disease | ||
| | | | ||
Line 2,471: | Line 2,620: | ||
| | | | ||
| | | | ||
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
|- | |- | ||
− | | | + | |[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]] |
|Disease | |Disease | ||
| | | | ||
Line 2,487: | Line 2,636: | ||
| | | | ||
| | | | ||
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES) | |CHAPTER 7 (GENETIC TUMOUR SYNDROMES) | ||
Line 2,539: | Line 2,672: | ||
----<br /> | ----<br /> | ||
|- | |- | ||
− | |Fanconi anaemia||Disease|| || || || || ||NA|| || | + | |[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease|| || || || || ||NA|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
|- | |- | ||
− | |Bloom syndrome||Disease|| || || || || ||NA|| || | + | |[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease|| || || || || ||NA|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
|- | |- | ||
− | |Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| || | + | |[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease|| || || || || ||NA|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
|- | |- | ||
− | |RASopathies||Disease|| || || || || ||NA|| || | + | |[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
|} | |} |
Revision as of 16:23, 16 April 2024
Welcome!
A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.
- For assignments, please see the "Author" column below (highlighted blue).
- If empty (no name is present), please volunteer to create content for that disease!
- If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
- To volunteer, please [Contact us] with your page of interest.
- Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parentheses) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition)(Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clonal haematopoiesis | Disease | Meenakshi Mehrotra | 4/8/24 | Pending | Fabiola Quintero-Rivera (FQR) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
Clonal cytopenias of undetermined significance | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Chronic myeloid leukaemia | Disease | PENDING | FQR | Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | Complete | Date page was created | |||||||
Chronic neutrophilic leukaemia | Disease | PENDING | FQR | Chronic Neutrophilic Leukemia (CNL) | Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally | Complete | Date page was created | |||||||
Chronic eosinophilic leukaemia | Disease | PENDING | FQR | Chronic Eosinophilic Leukemia, Not Otherwise Specified | Chelsea D. Kramish; Daynna J.Wolff | complete/pending faculty review | ||||||||
Polycythaemia vera | Disease | PENDING | FQR | Polycythemia Vera (PV) | Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | Complete | ||||||||
Essential thrombocythaemia | Disease | PENDING | FQR | Essential Thrombocythemia (ET) | Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | Complete | ||||||||
Primary myelofibrosis | Disease | PENDING | FQR | Primary Myelofibrosis (PMF) | T. Niroshi Senaratne, UCLA | Complete | 8/4/2020 before submission |
|||||||
Juvenile myelomonocytic leukaemia | Disease | PENDING | FQR | Juvenile Myelomonocytic Leukemia (JMML) | Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology
Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories |
PENDING importing content and reference formatting | FQR has emailed SR several times, last 4/20/22 | |||||||
Myeloproliferative neoplasm, NOS | Disease | PENDING | FQR | Myeloproliferative Neoplasm (MPN), Unclassifiable | Thomas Lee, MD, PhD, University of California, Los Angeles | Complete | ||||||||
Cutaneous mastocytosis | Disease | PENDING | FQR | Cutaneous Mastocytosis | S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | Complete | ||||||||
Systemic mastocytosis | Disease | PENDING | FQR | Systemic Mastocytosis | Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University | Complete | ||||||||
Mast cell sarcoma | Disease | PENDING | FQR | Mast Cell Sarcoma | Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | Complete | ||||||||
Myelodysplastic neoplasm with low blasts and 5q deletion | Disease | PENDING | FQR | Myelodysplastic Syndrome (MDS) with Isolated del(5q) | Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | Complete | ||||||||
Myelodysplastic neoplasm with low blasts and SF3B1 mutation | Disease | PENDING | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
Myelodysplastic neoplasm with biallelic TP53 inactivation | Disease | Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
Myelodysplastic neoplasm with low blasts | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Myelodysplastic neoplasm, hypoplastic | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Myelodysplastic neoplasm with increased blasts | Disease | PENDING | FQR | Myelodysplastic Syndrome (MDS) with Excess Blasts | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | Complete | ||||||||
Childhood myelodysplastic neoplasm with low blasts | Disease | PENDING | FQR | Refractory Cytopenia of Childhood | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | Complete | ||||||||
Childhood myelodysplastic neoplasm with increased blasts | Disease | PENDING | FQR | Refractory Cytopenia of Childhood | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | Complete | ||||||||
Chronic myelomonocytic leukaemia | Disease | PENDING | FQR | Chronic Myelomonocytic Leukemia (CMML) | Linsheng Zhang, MD, PhD | Complete | ||||||||
Myelodysplastic/myeloproliferative neoplasm with neutrophilia | Disease | PENDING | FQR | Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | Linsheng Zhang, MD, PhD | Complete | ||||||||
Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis | Disease | PENDING | FQR | Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | Complete | Date page was created | |||||||
Myelodysplastic/myeloproliferative neoplasm, NOS | Disease | PENDING | FQR | Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | Complete | ||||||||
Acute promyelocytic leukaemia with PML::RARA fusion | Disease | PENDING | Jennelle Hodge (JH)/ Malini Sathanoori (MS) | Acute Promyelocytic Leukemia (APL) with PML-RARA | Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. | Complete | 03/01/2021-MS (re-review) | |||||||
Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
Complete | 04/26/2021-MS (re-review) | |||||||
Acute myeloid leukaemia with CBFB::MYH11 fusion | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
Complete | 03/01/2021-MS (re-review) | |||||||
Acute myeloid leukaemia with DEK::NUP214 fusion | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 | Jennelle C. Hodge, PhD, FACMG | Complete | 02/24/2021-MS (re-review) | |||||||
Acute myeloid leukaemia with RBM15::MRTFA fusion | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 | Jennelle C. Hodge, PhD, FACMG | Complete | ||||||||
Acute myeloid leukaemia with BCR::ABL1 fusion | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with BCR-ABL1 | Kay Weng Choy MBBS, Monash Medical Centre | Complete | ||||||||
Acute myeloid leukaemia with KMT2A rearrangement | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 | Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. | Complete | 03/01/2021-MS (re-review) | |||||||
Acute myeloid leukaemia with MECOM rearrangement | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM | Gordana Raca MD PhD, University of Southern California, Los Angeles | Complete | Need permission for figure? Update WHO? | |||||||
Acute myeloid leukaemia with NUP98 rearrangement | Disease | Eric McGinnis, MD | 12/20/23 | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
Acute myeloid leukaemia with NPM1 mutation | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with Mutated NPM1 | Xinjie Xu, PhD, FACMG | Complete | Add WHO reference | |||||||
Acute myeloid leukaemia with CEBPA mutation | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA | Paul Defazio, MSc, Monash Health | Complete | ||||||||
Acute myeloid leukaemia, myelodysplasia-related | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
Acute myeloid leukaemia with other defined genetic alterations | Disease | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Acute myeloid leukaemia with minimal differentiation | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with Minimal Differentiation | Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | Complete | ||||||||
Acute myeloid leukaemia without maturation | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) without Maturation | Jennelle C. Hodge, PhD, FACMG | Complete | ||||||||
Acute myeloid leukaemia with maturation | Disease | PENDING | JH_MS | Acute Myeloid Leukemia (AML) with Maturation | Jennelle C. Hodge, PhD, FACMG | Complete | ||||||||
Acute basophilic leukaemia | Disease | PENDING | JH_MS | Acute Basophilic Leukemia | Ashwini Yenamandra PhD FACMG | Complete | ||||||||
Acute myelomonocytic leukaemia | Disease | PENDING | JH_MS | Acute Myelomonocytic Leukemia | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
Acute monocytic leukaemia | Disease | PENDING | JH_MS | Acute Monoblastic and Monocytic Leukemia | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
Acute erythroid leukaemia | Disease | PENDING | JH_MS | Pure Erythroid Leukemia | Ashwini Yenamandra PhD FACMG | Complete | ||||||||
Acute megakaryoblastic leukaemia | Disease | PENDING | JH_MS | Acute Megakaryoblastic Leukemia (AMKL) | Fei Yang, MD, FACMG Oregon Health & Science University |
Complete | ||||||||
Myeloid sarcoma | Disease | PENDING | JH_MS | Myeloid Sarcoma | Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine | Complete | ||||||||
RESOLVE 4th edition AML-Related NON-WHO entities content | Acute Myeloid Leukemia (AML) with Mutated FLT3 + Acute Myeloid Leukemia (AML) with NUP214-ABL1 + Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6 | ISSUE- FIX
|
||||||||||||
Myeloid neoplasm post cytotoxic therapy | Disease | PENDING | JH_MS | Therapy-Related Myeloid Neoplasms | Shawn A. Silver, DO, Shashi Shetty, Ph.D. | Complete | Check reference format | |||||||
Myeloid neoplasms associated with germline predisposition | Disease | PENDING | JH_MS | Multiple pages including overview page (Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)) and 6 disease pages ( HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation, HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation, HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation, HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation, HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation, HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation) | See links from instructions on the 5th edition page | Complete | Most were re-reviewed by MS on 03/02/2021 | For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022" | ||||||
Myeloid proliferations associated with Down syndrome | Disease | PENDING | JH_MS | MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | Complete (all three pages) | ||||||||
Myeloid/lymphoid neoplasm with PDGFRA rearrangement | Disease | PENDING | FQR | Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement | Jay Alden, DO | Complete | ||||||||
Myeloid/lymphoid neoplasm with PDGFRB rearrangement | Disease | PENDING | FQR | Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement | Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD | Complete | ||||||||
Myeloid/lymphoid neoplasm with FGFR1 rearrangement | Disease | PENDING | FQR | Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement | Yanna Ding, MD PhD | Complete | ||||||||
Myeloid/lymphoid neoplasm with JAK2 rearrangement | Disease | ISSUE- FIX
|
FQR | Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 (Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)) + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 (Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io) ) - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff | Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff | Complete | ||||||||
Myeloid/lymphoid neoplasm with FLT3 rearrangement | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes | Disease | FQR | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Mixed-phenotype acute leukaemia with BCR::ABL1 fusion | Disease | Tracy Tucker, PhD, FCCMG | 4/6/24 | Pending | JH_MS | Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 | Tracy Tucker, PhD, FCCMG | Complete | ||||||
Mixed-phenotype acute leukaemia with KMT2A rearrangement | Disease | Tracy Tucker, PhD, FCCMG | 4/6/24 | Pending | JH_MS | Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged | Tracy Tucker, PhD, FCCMG | Complete | ||||||
Acute leukaemia of ambiguous lineage with other defined genetic alterations | Disease | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Mixed-phenotype acute leukaemia, B/myeloid | Disease | PENDING | JH_MS | Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified | Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD | Complete | ||||||||
Mixed-phenotype acute leukaemia, T/myeloid | Disease | PENDING | JH_MS | Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | Complete | ||||||||
Mixed-phenotype acute leukaemia, rare types | Disease | PENDING | JH_MS | Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types | Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | PENDING | ||||||||
Acute leukaemia of ambiguous lineage, NOS | Disease | JH_MS | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Acute undifferentiated leukaemia | Disease | PENDING | JH_MS | Acute Undifferentiated Leukemia | Amelia Nakanishi, MD and Shashi Shetty, PhD | Complete | Check reference format | |||||||
CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm | Disease | Greg Corboy (GC) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Blastic plasmacytoid dendritic cell neoplasm | Disease | PENDING | GC | Blastic Plasmacytoid Dendritic Cell Neoplasm | Hao Liu, MD and Daynna J. Wolff, PhD | Complete | Previously within myeloid section under JH/MS editors | |||||||
Langerhans cell histiocytosis | Disease | PENDING | GC | Langerhans Cell Histiocytosis | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | Complete | 5/19/2022 |
Date completed by author: 04/28/2022 | ||||||
Langerhans cell sarcoma | Disease | PENDING | GC | Langerhans Cell Sarcoma | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | Complete | 5/19/2022 |
Date completed by author: 04/28/2022 | ||||||
Indeterminate dendritic cell tumour | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Interdigitating dendritic cell sarcoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Juvenile xanthogranuloma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Erdheim-Chester disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Rosai-Dorfman Disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
ALK-positive histiocytosis | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Histiocytic sarcoma | Disease | PENDING | GC | Histiocytic Sarcoma | Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic | Complete | 10/01/2021 | Date completed by author: 10/01/2021 | ||||||
CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reactive B-cell rich lymphoid proliferations that can mimic lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
IgG4-related disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Unicentric Castleman disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Idiopathic multicentric Castleman disease | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
KSHV/HHV8-associated multicentric Castleman disease | Disease | PENDING | GC | Multicentric Castleman Disease | Sudha Arumugam, MD | Complete | 01/24/2022 | Date completed by author: 01/24/2022 | ||||||
B-lymphoblastic leukaemia/lymphoma | Disease | PENDING | Holli Drendel (HD) | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified | Holli Drendel | PENDING | ||||||||
B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | PENDING | ||||||||
B-lymphoblastic leukaemia/lymphoma with hypodiploidy | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy | Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG | Complete | ||||||||
B-lymphoblastic leukaemia/lymphoma with iAMP21 | Disease | Holli Drendel | ?Complete? Looks like tables need more editing. | HD | B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli] | Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte | ?Complete | |||||||
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | PENDING | ||||||||
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine | Complete | ||||||||
B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged | Yassmine Akkari Nicolas Millan | PENDING | ||||||||
B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion | Disease | PENDING | HD | B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion | Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma | PENDING | ||||||||
B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features | Disease | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | PENDING | ||||||||
B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion | Disease | PENDING | HD | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | PENDING | ||||||||
B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion | Disease | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations | Disease | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
B-lymphoblastic leukaemia/lymphoma, NOS | Disease | HD | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
RESOLVE 4th edition ALL-Related NON-WHO entities content | B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | ISSUE- FIX
|
ISSUE - FIX | |||||||||||
Monoclonal B-cell lymphocytosis | Disease | PENDING; Shashirekha Shetty | Shivani Golem (SG) | Monoclonal B-cell Lymphocytosis | Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | PENDING, 4/30/2024 | Assigned 12/19/2022 with completion date of 1/19/2023 | |||||||
Chronic lymphocytic leukaemia/small lymphocytic lymphoma | Disease | Jaime Nagy, PhD, University of Iowa
Renee Eigsti, MD, Pathology Services of Kalamazoo Honey Reddi, PhD, Belay Diagnostics |
Complete | SG | Already converted to 5th edition | Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | ||||||||
Hairy cell leukaemia | Disease | SG | Hairy Cell Leukemia | Snehal Patel, MD, PhD | Complete | |||||||||
Splenic marginal zone lymphoma | Disease | SG | Splenic Marginal Zone Lymphoma | Snehal Patel, MD, PhD | Complete | |||||||||
Splenic diffuse red pulp small B-cell lymphoma | Disease | SG | Splenic Diffuse Red Pulp Small B-cell Lymphoma | Snehal Patel, MD, PhD | Complete | |||||||||
Splenic B-cell lymphoma/leukaemia with prominent nucleoli | Disease | SG | Hairy Cell Leukemia Variant | Snehal Patel, MD, PhD | Complete | |||||||||
Lymphoplasmacytic lymphoma | Disease | PENDING | SG | (1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | (1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | Complete | 4/12/2023 by FQR | |||||||
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | Disease | PENDING | SG | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI) |
Complete | 4/12/23 by FQR | |||||||
Primary cutaneous marginal zone lymphoma | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Nodal marginal zone lymphoma | Disease | PENDING | SG | Nodal Marginal Zone Lymphoma | Andrew Ly, DO and Shivani Golem, PhD, FACMG | Complete | 5/28/2021 | |||||||
Paediatric nodal marginal zone lymphoma | Disease | PENDING | SG | Paediatric Nodal Marginal Zone Lymphoma | * Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | Complete | 11/11/2020 | |||||||
In situ follicular B-cell neoplasm | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | 7/28/2023 | Pending | SG | In Situ Follicular Neoplasia | Rachel D. Burnside, PhD, MBA, FACMGG | Pending | ||||||
Follicular lymphoma | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | 7/28/2023 | Pending | SG | Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity | (1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma | (1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida | Pending | |||||
Paediatric-type follicular lymphoma | Disease | PENDING | SG | Paediatric-Type Follicular Lymphoma | *Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | Complete | 8/16/2020 | |||||||
Duodenal-type follicular lymphoma | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | 7/28/2023 | Pending | SG | Duodenal-Type Follicular Lymphoma | No prior content | |||||||
Primary cutaneous follicle centre lymphoma | Disease | PENDING | SG | Primary Cutaneous Follicle Centre Lymphoma | Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG | Complete | 09/10/2022 | |||||||
In situ mantle cell neoplasm | Disease | PENDING | SG | In Situ Mantle Cell Neoplasia | Rina Kansal, MD; Versiti Blood Center of Wisconsin | Complete | 7/26/2022 | |||||||
Mantle cell lymphoma | Disease | PENDING | SG | Mantle Cell Lymphoma | Mahsa Khanlari, MD and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | Pending | Target completion date 8/15/20 | |||||||
Leukaemic non-nodal mantle cell lymphoma | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Transformations of indolent B-cell lymphomas | Disease | SG | Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
Diffuse large B-cell lymphoma, NOS | Disease | PENDING | GC | Diffuse Large B-cell Lymphoma, Not Otherwise Specified | Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | Pending | Requested to update 14022022 | |||||||
T-cell/histiocyte-rich large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements | Disease | PENDING | GC | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | Complete | 24/02/2022 | |||||||
ALK-positive large B-cell lymphoma | Disease | PENDING | GC | ALK-Positive Large B-cell Lymphoma | Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | Pending | Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |||||||
Large B-cell lymphoma with IRF4 rearrangement | Disease | PENDING | GC | Large B-cell Lymphoma with IRF4 Rearrangement | Afia Hasnain, MBBS, PhD | Complete | 5/26/2021 | |||||||
High grade B-cell lymphoma with 11q aberrations | Disease | PENDING | GC | Burkitt-Like Lymphoma with 11q Aberration | Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | Comlete | 27/01/2022 | |||||||
Lymphomatoid granulomatosis | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
EBV-positive diffuse large B-cell lymphoma | Disease | Fnu Monika (trainee) + Andrew Siref as mentor | 3/22/24 | Pending | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
Diffuse large B-cell lymphoma associated with chronic inflammation | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Fibrin-associated large B-cell lymphoma | Disease | PENDING | GC | Note: previously a subset DLBCL assoc with chronic inflam | Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
Fluid overload-associated large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Plasmablastic lymphoma | Disease | PENDING | GC | Plasmablastic Lymphoma | Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | Complete | 28/03/2022 | |||||||
Primary large B-cell lymphoma of immune-privileged sites | Disease | PENDING | GC | (1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | (1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | (1) Pending + (2) Complete | (1) Not ready + (2) 03/28/22 | For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022 | ||||||
Primary cutaneous diffuse large B-cell lymphoma, leg type | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Intravascular large B-cell lymphoma | Disease | PENDING | GC | Intravascular Large B-cell Lymphoma | Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | Complete | 9/1/22 | Emailed 28/3/2022 for progress update | ||||||
Primary mediastinal large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Mediastinal grey zone lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
High-grade B-cell lymphoma, NOS | Disease | PENDING | GC | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | Aiko Otsubo, PhD, Indiana University, Holli Drendel | Complete | 16/11/2021 | |||||||
Burkitt lymphoma | Disease | PENDING | GC | Burkitt Lymphoma | Becky Leung, MBBS (Hons), BSc, Pathology Queensland | Complete | 28/06/2021 | |||||||
Primary effusion lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
KSHV/HHV8-positive diffuse large B-cell lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
KSHV/HHV8-positive germinotropic lymphoproliferative disorder | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Hyperplasias arising in immune deficiency/dysregulation | Disease | FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content. What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page. | GC | |||||||||||
Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation | Disease | FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders.
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)" |
GC | Polymorphic Post-Transplant Lymphoproliferative Disorders | Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) | Completed | 26/4/2022 | |||||||
EBV-positive mucocutaneous ulcer | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Lymphomas arising in immune deficiency / dysregulation | Disease | FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others" | GC | |||||||||||
Inborn error of immunity-associated lymphoid proliferations and lymphomas | Disease | FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5. | GC | |||||||||||
Classic Hodgkin lymphoma | Disease | PENDING | GC | Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | (1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | (1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | Pending + Completed (03/21/22) | Not completed for checking (1, 3 and 4) + 03/21/22 (2) | ||||||
Nodular lymphocyte predominant Hodgkin lymphoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Cold agglutinin disease | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
IgM monoclonal gammopathy of undetermined significance | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Non-IgM monoclonal gammopathy of undetermined significance | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Monoclonal gammopathy of renal significance | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Immunoglobulin-related (AL) amyloidosis | Disease | PENDING | SG | Primary Amyloidosis | Heather E. Williams, PhD, MS, PgD, ErCLG | ?PENDING |
||||||||
Monoclonal immunoglobulin deposition disease | Disease | PENDING | SG | Light Chain and Heavy Chain Deposition Disease | Chen Yang, MD, PhD, University of Michigan | Complete | 10/15/2022 | |||||||
Mu heavy chain disease | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Gamma heavy chain disease | Disease | PENDING | SG | Gamma Heavy Chain Disease | Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA | Complete | 5/26/2021 | |||||||
Alpha heavy chain disease | Disease | SG | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Plasmacytoma | Disease | PENDING | SG | author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) | NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
Plasma cell myeloma / multiple myeloma | Disease | PENDING | SG | Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | (1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | (1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | Pending | |||||||
Plasma cell neoplasms with associated paraneoplastic syndrome | Disease | PENDING | SG | Note: author needs to include POEMS, TEMPI, and look for AESOP content | (1) POEMS Syndrome + (2) TEMPI Syndrome | (1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | ?PENDING | |||||||
Disease (5th Edition) | Page Type | Author (5th Edition) (Note: please indicate trainees in parenthesis) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Content Status (5th Edition) (Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review (5th Edition) | Notes (5th Edition) | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) | Prior Content Status (4th Edition) (Pending or Complete) | Prior Date of Last Editor Review (4th Edition) | Prior Notes (4th Edition) |
CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kikuchi-Fujimoto disease | Disease | Sumi Kitahara (SK) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Autoimmune lymphoproliferative syndrome | Disease | Aviv Oren, MD (trainee), Karin Miller, MD | 3/25/2024 | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
Indolent T-lymphoblastic proliferation | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
T-lymphoblastic leukaemia / lymphoma, NOS | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Early T-precursor lymphoblastic leukaemia / lymphoma | Disease | Fei Yang, MD | Pending | SK | Early T-Cell Precursor Lymphoblastic Leukemia | Fei Yang, MD, FACMG, Kaiser Permanente Northwest | Pending | |||||||
T-prolymphocytic leukaemia | Disease | Parastou Tizro, MD (trainee);
Sumire Kitahara, MD |
3/17/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
T-large granular lymphocytic leukaemia | Disease | Michelle Don, MD, MS | 3/17/2024 | 6/30/24 | Pending | SK | T-cell Large Granular Lymphocytic Leukemia | Michelle Don, MD, MS | Pending | |||||
NK-large granular lymphocytic leukaemia | Disease | Hailee St. Louis (trainee);
Michelle Don, MD, MS |
3/17/2024 | 6/30/24 | Pending | SK | Chronic Lymphoproliferative Disorder of NK Cells | Michelle Don, MD | Pending | |||||
Adult T-cell leukaemia/lymphoma | Disease | SK | Adult T-cell Leukemia/Lymphoma | Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | ?Pending | |||||||||
Sezary syndrome | Disease | Daynna J. Wolff, PhD | 3/22/2024 | SK | Sézary Syndrome | Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | Pending | |||||||
Aggressive NK-cell leukaemia | Disease | PENDING | SK | Aggressive NK-cell Leukemia | Shanelle De Lancy, MD, Shashirekha Shetty, PhD | ?Pending | ||||||||
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder | Disease | Amanda Xu, MD/MSc | 3/19/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder | Disease | Ahmed Eladely (trainee),
Andrew Siref, MD |
4/12/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
Mycosis fungoides | Disease | Daynna J. Wolff, PhD | 3/22/2024 | SK | Mycosis Fungoides | Jane Scribner, MD and Daynna J. Wolff, PhD | Pending | |||||||
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma | Disease | PENDING | SK | Primary Cutaneous Anaplastic Large Cell Lymphoma | Theresa Spivey, MD, Shashirekha Shetty, PhD | Pending | ||||||||
Subcutaneous panniculitis-like T-cell lymphoma | Disease | Raniah Alamri (Hemepath trainee) | 3/19/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
Primary cutaneous gamma/delta T-cell lymphoma | Disease | Mahzad Azimpouran (trainee); Sumire Kitahara, MD | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||||
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma | Disease | Ahmed Eladely (trainee),
Andrew Siref, MD |
4/12/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
Primary cutaneous peripheral T-cell lymphoma, NOS | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Indolent T-cell lymphoma of the gastrointestinal tract | Disease | SK | Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | Pending | |||||||||
Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Enteropathy-associated T-cell lymphoma | Disease | Fnu Monika, MBBS (trainee),
Andrew Siref, MD |
3/20/2024 | Pending | SK | Enteropathy-Associated T-cell Lymphoma | *Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | Complete | 1/21/2021 | |||||
Monomorphic epitheliotropic intestinal T-cell lymphoma | Disease | Fnu Monika, MBBS (trainee),
Andrew Siref, MD |
3/20/2024 | Pending | SK | Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | Pending | ||||||
Intestinal T-cell lymphoma, NOS | Disease | SK | Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | Complete | 9/26/2022 | ||||||||
Hepatosplenic T-cell lymphoma | Disease | Forough Sargolzaeiaval (trainee);
Michelle Don, MD, MS |
3/19/2024 | 6/30/24 | Pending | SK | Hepatosplenic T-cell Lymphoma | Michelle Don, MD, MS | Complete | 1/21/2021 | ||||
ALK-positive anaplastic large cell lymphoma | Disease | Miguel Gonzalez Mancera, MD (trainee)
Sumire Kitahara, MD |
Pending | SK | Anaplastic Large Cell Lymphoma, ALK-Positive | Miguel Gonzalez Mancera, MD
Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA |
Complete | 09/23/2022 | ||||||
ALK-negative anaplastic large cell lymphoma | Disease | Miguel Gonzalez Mancera, MD (trainee)
Sumire Kitahara, MD |
Pending | SK | Anaplastic Large Cell Lymphoma, ALK-Negative | Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | Complete | 09/23/2022 | ||||||
Breast implant-associated anaplastic large cell lymphoma | Disease | Lynne Abruzzo, MD, PhD | 4/1/2024 | Pending | SK | Breast Implant-Associated Anaplastic Large Cell Lymphoma | Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | Pending | ||||||
Nodal TFH cell lymphoma, angioimmunoblastic-type | Disease | Rachel Burnside, PhD | 7/28/2023 | Pending | SK | prior authors not available | Angioimmunoblastic T-cell Lymphoma | Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | Pending | |||||
Nodal TFH cell lymphoma, follicular-type | Disease | Rachel Burnside, PhD | 7/28/2023 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
Nodal TFH cell lymphoma, NOS | Disease | SK | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | Pending | |||||||||
Peripheral T-cell lymphoma, NOS | Disease | Bo Hong, MD | 6/25/2023 | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
EBV-positive nodal T- and NK-cell lymphoma | Disease | Fnu Monika, MBBS (trainee), Andrew Siref, MD | 3/22/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
Extranodal NK/T-cell lymphoma | Disease | Amanda Xu, MD/MSc | 3/19/2024 | Pending | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | ||||
Severe mosquito bite allergy | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Hydroa vacciniforme lymphoproliferative disorder | Disease | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Systemic chronic active EBV disease | Disease | Karin Miller, MD | 3/25/2024 | SK | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||
Systemic EBV-positive T-cell lymphoma of childhood | Disease | Karin Miller, MD | 3/25/2024 | SK | prior authors not available | Systemic EBV-Positive T-cell Lymphoma of Childhood | Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | Complete | 11/21/2021 | |||||
CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Follicular dendritic cell sarcoma | Disease | PENDING | GC | Follicular Dendritic Cell Sarcoma | Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | ?Pending | ||||||||
EBV-positive inflammatory follicular dendritic cell sarcoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Fibroblastic reticular cell tumour | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Intranodal palisaded myofibroblastoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Littoral cell angioma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Splenic hamartoma | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Sclerosing angiomatoid nodular transformation (SANT) of spleen | Disease | GC | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
CHAPTER 7 (GENETIC TUMOUR SYNDROMES) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fanconi anaemia | Disease | NA | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Bloom syndrome | Disease | NA | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
Ataxia-telangiectasia syndrome | Disease | NA | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | |||||||
RASopathies | Disease | NA | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) | NEW (No Prior) |